However, the emergence of innovative anti‐HER2 ADCs has revealed through the findings of the DESTINY‐Breast04 trial that individuals with HER2‐low BC can also derive advantages from DS‐8201a treatment.22 Here, ERBB2 is linked to breast cancer.